EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Study Number

1578122

Phase

N/A

Age Group

Adult

Principal Investigator

Deepak Vadehra

Purpose

The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.

Check your eligibility for this trial

Check now

Full Title

A Phase 0 Study of EGF-depleting therapy CIMAvax-EGF in Combination with Standard Therapy for RAS- and BRAF wild-type Metastatic Colorectal Cancer

ClinicalTrials.Gov ID

NCT06011772

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.